- Home
- About
- Find staff
- Igal Rosenstein
Igal Rosenstein
Affiliated to Research
Department of Clinical Neuroscience-
Association of Complement Factors With Disability Progression in Primary Progressive Multiple
Sclerosis
Jan D. Lunemann, Harald Hegen, Luisa Maria Villar, Konrad Rejdak, Augusto Sao-Aviles, Pere Carbonell-Mirabent, Jaume Sastre-Garriga, Neus Mongay-Ochoa, Klaus Berek, Sergio Martinez-Yelamos, Francisco Perez-Miralles, Ahmed Abdelhak, Franziska Bachhuber, Hayrettin Tumani, Jan Lycke, Igal Rosenstein, Roberto Alvarez-Lafuente, Tamara Castillo-Trivino, David Otaegui, Sara Llufriu, Yolanda Blanco, Antonio J. Sanchez Lopez, Juan Antonio Garcia Merino, Nicolas Fissolo, Lucia Gutierrez, Javier Villacieros-alvarez, Enric Monreal, Adrian Valls-Carbo, Heinz Wiendl, Xavier Montalban, Manuel Comabella
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION - 2024 -
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré
syndrome
Brynhildur Hafsteinsdottir, Helen H. Farman, Nina Lagerstrom, Henrik Zetterberg, Oluf Andersen, Lenka Novakova, Bengt Nellgård, Hans Rosén, Clas Malmeström, Igal Rosenstein, Jan Lycke, Markus Axelsson
JOURNAL OF NEUROLOGY - 2024 -
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple
sclerosis.
Igal Rosenstein, Anna Nordin, Hemin Sabir, Clas Malmeström, Kaj Blennow, Markus Axelsson, Lenka Novakova
Journal of neurology - 2024 -
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center
study
Magnus Johnsson, Y. T. Stenberg, H. H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Sofia Sandgren, Igal Rosenstein, Jan Lycke, Markus Axelsson, Lenka Novakova
MULTIPLE SCLEROSIS JOURNAL - 2024 -
Serum biomarker levels predict disability progression in patients with primary progressive multiple
sclerosis
N. Fissolo, P. Benkert, J. Sastre-Garriga, N. Mongay-Ochoa, A. Vilaseca-Jolonch, S. Llufriu, Y. Blanco, H. Hegen, K. Berek, F. Perez-Miralles, K. Rejdak, L. M. Villar, E. Monreal, R. Alvarez-Lafuente, O. K. Soylu, A. Abdelhak, F. Bachhuber, H. Tumani, S. Martínez-Yélamos, A. J. Sánchez-López, A. García-Merino, L. Gutiérrez, T. Castillo-Trivino, Jan Lycke, Igal Rosenstein, R. Furlan, M. Filippi, N. Téllez, L. Ramió-Torrentà, J. D. Lünemann, H. Wiendl, S. Eichau, M. Khalil, J. Kuhle, X. Montalban, M. Comabella
Journal of Neurology Neurosurgery and Psychiatry - 2024 -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmeström, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurology - 2023 -
Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple
sclerosis.
Lenka Novakova, Marcus Henricsson, Elias Björnson, Markus Axelsson, Jan Borén, Igal Rosenstein, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Multiple sclerosis and related disorders - 2023 -
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis - a multicentre
study
Harald Hegen, Klaus Berek, Paola Cavalla, Mikael Christiansen, Andreja Emersic, Massimiliano Di Filippo, Lorenzo Gaetani, Michaela Hassler, Cyra Leurs, Dejan Milosavljevic, Vincent van Pesch, Thor Petersen, Stefan Presslauer, Igal Rosenstein, Uros Rot, Christine Schnabl, Charlotte Teunissen, Domizia Vecchio, Marco Vercellino, Florian Deisenhammer
FRONTIERS IN IMMUNOLOGY - 2023 -
Diagnostic, Prognostic, and Disease Activity Biomarkers in Multiple
Sclerosis
Igal Rosenstein
2023 -
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, S. Rasch, Kaj Blennow, Henrik Zetterberg, Jan Lycke
FRONTIERS IN IMMUNOLOGY - 2023 -
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled
trial
A. Svenningsson, T. Frisell, J. Burman, J. Salzer, K. Fink, S. Hallberg, J. Hambraeus, Markus Axelsson, F. Al Nimer, P. Sundstrom, M. Gunnarsson, R. Johansson, J. Mellergard, Igal Rosenstein, A. Ayad, I. Sjoblom, A. Risedal, P. de Flon, Eric Gilland, J. Lindeberg, F. Shawket, F. Piehl, Jan Lycke
Lancet Neurology - 2022 -
Four Swedish cases of CSF1R-related leukoencephalopathy: Visualization of clinical
phenotypes
Igal Rosenstein, Oluf Andersen, Daniel Victor, Elisabet Englund, Tobias Granberg, Carola Oldfors Hedberg, Katarina Jood, Yusran Ady Fitrah, Takeshi Ikeuchi, Virginija Danylaité Karrenbauer
Acta Neurologica Scandinavica - 2022 -
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple
sclerosis
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Frontiers in Immunology - 2022 -
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based
study
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world
investigation
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurochemistry - 2021